256 related articles for article (PubMed ID: 15745980)
1. Risks and benefits of phase 1 oncology trials, 1991 through 2002.
Horstmann E; McCabe MS; Grochow L; Yamamoto S; Rubinstein L; Budd T; Shoemaker D; Emanuel EJ; Grady C
N Engl J Med; 2005 Mar; 352(9):895-904. PubMed ID: 15745980
[TBL] [Abstract][Full Text] [Related]
2. Risks and benefits associated with novel phase 1 oncology trial designs.
Koyfman SA; Agrawal M; Garrett-Mayer E; Krohmal B; Wolf E; Emanuel EJ; Gross CP
Cancer; 2007 Sep; 110(5):1115-24. PubMed ID: 17628485
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic response in phase I trials of antineoplastic agents.
Estey E; Hoth D; Simon R; Marsoni S; Leyland-Jones B; Wittes R
Cancer Treat Rep; 1986 Sep; 70(9):1105-15. PubMed ID: 3527410
[TBL] [Abstract][Full Text] [Related]
4. Descriptions of benefits and risks in consent forms for phase 1 oncology trials.
Horng S; Emanuel EJ; Wilfond B; Rackoff J; Martz K; Grady C
N Engl J Med; 2002 Dec; 347(26):2134-40. PubMed ID: 12501226
[TBL] [Abstract][Full Text] [Related]
5. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
6. A clinical development paradigm for cancer vaccines and related biologics.
Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
[TBL] [Abstract][Full Text] [Related]
7. Survival and prognostic factors in lung cancer patients treated in phase I trials: Japanese experience.
Yamamoto N; Tamura T; Fukuoka M; Saijo N
Int J Oncol; 1999 Oct; 15(4):737-41. PubMed ID: 10493956
[TBL] [Abstract][Full Text] [Related]
8. Presentation and subsequent publication rates of phase I oncology clinical trials.
Camacho LH; Bacik J; Cheung A; Spriggs DR
Cancer; 2005 Oct; 104(7):1497-504. PubMed ID: 16116590
[TBL] [Abstract][Full Text] [Related]
9. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
10. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
11. Participants in phase 1 oncology research trials: are they vulnerable?
Seidenfeld J; Horstmann E; Emanuel EJ; Grady C
Arch Intern Med; 2008 Jan; 168(1):16-20. PubMed ID: 18195190
[TBL] [Abstract][Full Text] [Related]
12. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
13. Toxicity-evaluation designs for phase I/II cancer immunotherapy trials.
Messer K; Natarajan L; Ball ED; Lane TA
Stat Med; 2010 Mar; 29(7-8):712-20. PubMed ID: 20213706
[TBL] [Abstract][Full Text] [Related]
14. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials.
Roberts TG; Goulart BH; Squitieri L; Stallings SC; Halpern EF; Chabner BA; Gazelle GS; Finkelstein SN; Clark JW
JAMA; 2004 Nov; 292(17):2130-40. PubMed ID: 15523074
[TBL] [Abstract][Full Text] [Related]
15. Vinorelbine (Navelbine) in the treatment of breast cancer: the European experience.
Fumoleau P; Delozier T; Extra JM; Canobbio L; Delgado FM; Hurteloup P
Semin Oncol; 1995 Apr; 22(2 Suppl 5):22-8; discussion 28-9. PubMed ID: 7740332
[TBL] [Abstract][Full Text] [Related]
16. Pediatric phase I trials in oncology: an analysis of study conduct efficiency.
Lee DP; Skolnik JM; Adamson PC
J Clin Oncol; 2005 Nov; 23(33):8431-41. PubMed ID: 16293874
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib for the treatment of advanced renal cell carcinoma.
Kane RC; Farrell AT; Saber H; Tang S; Williams G; Jee JM; Liang C; Booth B; Chidambaram N; Morse D; Sridhara R; Garvey P; Justice R; Pazdur R
Clin Cancer Res; 2006 Dec; 12(24):7271-8. PubMed ID: 17189398
[TBL] [Abstract][Full Text] [Related]
18. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
19. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
20. Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer.
Tkaczuk KH
Clin Ther; 2009; 31 Pt 2():2273-89. PubMed ID: 20110041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
